financetom
Business
financetom
/
Business
/
Johnson & Johnson's Talc Litigation Risks 'Likely' Manageable, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson's Talc Litigation Risks 'Likely' Manageable, RBC Says
Apr 2, 2025 8:44 AM

11:16 AM EDT, 04/02/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) talc litigation risks are "likely" manageable as the drugmaker is going back to the tort system to fight what it deems "junk science," RBC Capital Markets said in a note Monday.

The company said late Monday that the US Bankruptcy Court for the Southern District of Texas denied its subsidiary Red River Talc's request to confirm its proposed prepackaged bankruptcy plan.

RBC said Johnson & Johnson's ( JNJ ) return to the tort system is "prudent" because it has had prior success there, winning 16 of 17 cases in the last 11 years. The firm also noted that the company will do the Daubert Challenge that places the burden on the plaintiff to prove the scientific validity of their opinion, which could potentially end federal cases.

RBC added that the company has a "strong" cash position and hasn't changed its 2025 guidance.

The firm maintained an outperform rating on the stock with a $181 price target.

Shares were up 1.4% in recent trading.

Price: 155.37, Change: +2.12, Percent Change: +1.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chinese companies turn to generics as shipments behind US weight-loss craze fade
Chinese companies turn to generics as shipments behind US weight-loss craze fade
Sep 2, 2025
NEW YORK (Reuters) -Some Chinese companies now racing to make generic versions of Novo Nordisk's Wegovy also supplied ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the U.S. over the past two years, according to three sources and a Reuters review of shipping and public records. Cheap copies of Wegovy and Eli Lilly's (...
FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade
FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade
Sep 2, 2025
* At least eight Chinese companies supplied raw ingredients for weight-loss drugs to US compounding pharmacies * In 2024, imports were enough for at least 1 billion starter doses * Novo's key semaglutide patent expires next year in Canada, Brazil * (Adds FDA comment in paragraph 26) By Patrick Wingrove NEW YORK, Sept 2 (Reuters) - Some Chinese companies now...
PRESS DIGEST- Financial Times - September 3
PRESS DIGEST- Financial Times - September 3
Sep 2, 2025
Sept 3 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Thames Water creditors pledge more investment to try to seal rescue deal - US group's acquisition of top UK wealth managers heralds new consolidation push - Starmer considers digital ID rollout...
Google keeps Chrome and Apple deal but must share data in big antitrust ruling
Google keeps Chrome and Apple deal but must share data in big antitrust ruling
Sep 2, 2025
(Reuters) -Google won't have to sell its Chrome browser, a judge in Washington said on Tuesday, handing a rare win to Big Tech in its battle with U.S. antitrust enforcers, but ordering Google to share data with rivals to open up competition in online search. Google parent Alphabet's shares were up 7.2% in extended trading on Tuesday as investors cheered...
Copyright 2023-2026 - www.financetom.com All Rights Reserved